Synergy Pharmaceuticals Reports 2013 Fourth Quarter And Full-Year Financial Results
Published: Mar 18, 2014
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Help employers find you! Check out all the jobs and post your resume.